Compass Therapeutics, Inc.

CMPX · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders12.5%

Institutions88.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2020-03-31	2019-03-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	–	–	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$72.84M	-$56.63M	-$50.36M	-$41.66M	-$81.88M	-$27.81M	-$32105	-$32759
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$66.49M	-$49.38M	-$42.49M	-$39.23M	-$82.18M	-$29.50M	-$37483	-$36037
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$0.00	$0.00	$0.00	$-1.31	$-0.96	$0.00	$0.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2020-03-31	2019-03-31
Cash and highly liquid short-term investments the company can access almost immediately.	$30.60M	$43.50M	$24.20M	$34.90M	$144.51M	$47.08M	$3745	$4866
Everything the company owns that has value — cash, property, inventory, investments, and more.	$219.59M	$140.40M	$156.88M	$199.65M	$153.76M	–	$3745	$4866
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	$0	$9.33M	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$22.80M	$15.17M	$8.34M	$18.01M	$13.68M	–	$111817	$75455
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$196.79M	$125.23M	$148.54M	$181.64M	$140.08M	–	-$108072	-$70589

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2020-03-31	2019-03-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$49.14M	-$44.85M	-$40.62M	-$34.13M	-$19.67M	-$26.80M	-$32106	-$32759
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$25000	$44000	$30000	$212000	$1.57M	$106000	–	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$49.17M	-$44.90M	-$40.65M	-$34.34M	-$21.23M	-$26.91M	–	–

Compass Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison